Adicet Bio (ACET) Cash from Financing Activities (2017 - 2026)
Adicet Bio (ACET) posted quarterly Cash from Financing Activities of -$65000.0 for Q1 2026, up 37.5% year-over-year from -$47272.7 in Q1 2025, and down 100.09% quarter-over-quarter from $75.2 million in Q4 2025.
Adicet Bio (ACET) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Adicet Bio's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$65000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 37.5% year-over-year to -$65000.0; the TTM figure through Mar 2026 stood at $75.3 million (up 31665.4% YoY), while the FY2025 annual figure was $75.2 million, down 32.4% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$65000.0, down from $75.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $111.0 million in Q1 2024, with the low at -$1.1 million in Q1 2022.
- The 5-year median for Cash from Financing Activities is $150000.0 (2022), against an average of $14.3 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 100.78% in 2022, then surged 1585328.57% in 2024.
- Adicet Bio's Cash from Financing Activities stood at $304000.0 in 2022, then slumped by 75.0% to $76000.0 in 2023, then surged by 80.26% to $137000.0 in 2024, then soared by 54813.87% to $75.2 million in 2025, then plunged by 100.09% to -$65000.0 in 2026.
- Business Quant data shows ACET's Cash from Financing Activities at -$65000.0 in Q1 2026, $75.2 million in Q4 2025, and -$150000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Adicet Bio | 98.21 Mn | -19.98 Mn | - | 58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58,000.00 |
| Jun 30, 2026 | 58,000.00 |
| Mar 31, 2026 | -65,000.00 |
| Mar 31, 2026 | -65,000.00 |
| Dec 31, 2025 | 75.23 Mn |
| Dec 31, 2025 | 75.23 Mn |
| Sep 30, 2025 | -150,000.00 |
| Sep 30, 2025 | -150,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Mar 31, 2025 | -104,000.00 |
| Mar 31, 2025 | -104,000.00 |
| Dec 31, 2024 | 137,000.00 |
| Dec 31, 2024 | 137,000.00 |
| Jun 30, 2024 | 204,000.00 |
| Jun 30, 2024 | 204,000.00 |
| Mar 31, 2024 | 110.97 Mn |
| Mar 31, 2024 | 110.97 Mn |
| Dec 31, 2023 | 76,000.00 |
| Dec 31, 2023 | 76,000.00 |